The QTc workshop hosted by Richmond Pharmacology on 29th September was deemed a huge success. Representatives from top pharmaceutical companies gathered at St George's Hospital to enjoy first class seminars given by world leading experts in cardiology.Jörg Täubel, Managing Director of Richmond Pharmacology began the proceedings by welcoming guests and introducing the speakers for the day.Professor John Camm, Chairman of the Department of Cardiac and Vascular Sciences at St George's Hospital Medical School, the first to speak, defined the QT interval and its clinical relevance. He later provided an insight into the factors that influence the QT interval.Dr Elijah Behr from St George's Hospital Medical School gave a detailed presentation on the congenital syndromes of abnormal ventricular repolarisation. Dr Behr also reflected on the important role that pharmacogenomics will play in the development of drugs in the near future.Professor Marek Malik, also from St George's Hospital Medical School took to the rostrum after coffee to talk about the correction or control of the QT interval for heart rate. Later in the day, Professor Malik returned to give an entertaining presentation on how the QT interval should be measured and the possible implications of all these factors in Study Design.After a delicious buffet lunch, Dr Rashmi Shah from the MHRA, gave an insightful presentation on the regulatory aspects of drug induced QTinterval prolongation, and finished the workshop with a talk entitled The Definitive QT Study, which highlighted the importance of inclusion of such studies in adequate drug development programmes.Initial feedback from those that attended the workshop has been outstanding, everyone benefited from the highly educational and enjoyable day.Richmond Pharmacology continues to work closely with St George's Hospital Medical School to ensure we provide the expertise required for QTc studies. For more information on Richmond Pharmacology's QTc capabilities, please visit our services page.The event was filmed and will be available as a DVD pack in November.

Latest news

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

Events

Swiss Biotech Day 2025

5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event